Sarepta Therapeutics (SRPT) Finished Goods (2016 - 2026)

Sarepta Therapeutics' Finished Goods history runs 11 years deep, the most recent figure standing at $58.0 million for Q1 2026.

• In Q1 2026, Finished Goods fell 5.54% year-over-year to $58.0 million; the TTM figure through Mar 2026 stood at $58.0 million (down 5.54% YoY), while the FY2025 annual figure was $65.3 million, up 38.36% from the prior year.
• Finished Goods was $58.0 million for Q1 2026 at Sarepta Therapeutics, down from $65.3 million in the prior quarter.
• In the past five years, Finished Goods ranged from a high of $78.0 million in Q3 2024 to a low of $33.9 million in Q1 2022.
• Historically, Finished Goods has averaged $52.6 million across 5 years, with a median of $49.3 million in 2022.
• The sharpest annual moves came in 2022 and 2024: Finished Goods soared 83.58% in 2022, then dropped 23.62% in 2024.
• A 5-year view of Finished Goods shows it stood at $38.1 million in 2022, then surged by 62.02% to $61.8 million in 2023, then decreased by 23.62% to $47.2 million in 2024, then soared by 38.36% to $65.3 million in 2025, then retreated by 11.24% to $58.0 million in 2026.
• The last three Finished Goods figures came in at $58.0 million (Q1 2026), $65.3 million (Q4 2025), and $64.8 million (Q3 2025), per Business Quant data.